BioFire
BioMérieux Q3 Revenues Dip Slightly
The firm confirmed its full-year guidance for organic sales growth of between 4 percent and 6 percent.
BioMérieux Gets CLIA Waiver for BioFire SpotFire Respiratory Panel Mini
The CLIA waiver now allows the SpotFire system and two existing panels to be used by non-lab professionals at the point of care, the firm said.
BioMérieux Q1 Revenues Rise 8 Percent
The firm saw revenue growth across almost all business divisions, with a 32 percent jump in BioFire portfolio sales.
Multicenter Study Finds BioFire Joint Infection Panel Shows High Accuracy Despite Limitations
Premium
The assay received de novo authorization from the US Food and Drug Administration and CE-IVD marking last year.
Company executives highlighted recent and upcoming product launches expected to drive growth in its molecular, microbiology, and immunoassay businesses.
Feb 16, 2023
Jan 28, 2022
Sep 1, 2021
BioMérieux H1 Revenues Rise 7 Percent
Aug 31, 2021
Nov 6, 2020
Oct 22, 2020